Biomarkers of Synaptic Damage in Multiple Sclerosis
About this study
A prospective and retrospective cohort study of about five years will be performed on blood and cerebrospinal fluid samples taken for diagnostic reasons from recruited patients within the Neuromed Neurology Unit. Subjects with other chronic neurodegenerative diseases such as Amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD) and Parkinson's disease (PD), and healthy subjects subjected to blood sampling and / or lumbar puncture for clinical reasons will be recruited As control groups.
- Condition
- Multiple Sclerosis, Parkinson Disease, Amyotrophic Lateral Sclerosis, Alzheimer Disease
- Tested
- lumbar puncture
- Sponsor
- Neuromed IRCCS
Who can join
- Age
- 18 to 65 years
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 7
- Minimum age: 18 years
- Maximum age: 65 years
- Study condition: Multiple Sclerosis, Parkinson Disease, Amyotrophic Lateral Sclerosis, Alzheimer Disease
- Male and female patients (age between 18 and 65 years)
- Diagnosis of MS in accordance with McDonald's (2010 rev) criteria,
- EDSS between 0 and 5.5 (included),
- Patients able to provide informed consent to participation in the study
Exclusion 5
- Inability to provide informed written consent
- Altered basal blood count
- Pregnancy or lactation
- Contraindications for the execution of magnetic resonance imaging with gadolinium
- Significant clinical conditions in addition to SM or other chronic neurodegenerative diseases including latent viral infections
Where
1 site, 1 recruiting
IRCCS Neuromed
Pozzilli, Isernia, Italy
Contact
-
Diego Centonze, MD
+39 3934444159 centonze@uniroma2.it
-
Mario Stampanoni Bassi, MD
+39 3460181370 mario_sb@hotmail.it
Potential match only. Final eligibility is determined by the study team.